Viridian Therapeutics, Inc.\DE Balance Sheet
VRDN / Health Care|13 years of annual SEC 10-K data (FY2013-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 13 fiscal years. All figures from audited SEC 10-K filings.
Viridian Therapeutics, Inc.\DE had $899M in total assets and $722M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $874.7M | $717.6M | $477.4M | $424.6M | $197.0M | $127.6M | $26.8M | $32.6M | $47.4M | $22.1M | $21.2M | - | $209.0K |
| Accounts Receivable | - | - | - | - | - | - | $108.0K | $24.0K | $1.5M | $20.0K | $394.0K | $1.1M | $994.0K |
| Inventory | - | - | - | - | - | - | - | - | - | $64.0K | $187.0K | $179.0K | $357.0K |
| Current Assets | $894.2M | $738.5M | $486.5M | $431.2M | $200.2M | $129.6M | $29.7M | $65.4M | $51.9M | $23.9M | $11.7M | $6.8M | $2.1M |
| PP&E (Net) | $1.2M | $1.2M | $1.7M | $1.3M | $375.0K | $309.0K | $523.0K | $727.0K | $563.0K | $625.0K | $1.2M | $1.2M | $928.0K |
| Total Assets | $899.4M | $742.4M | $490.4M | $435.1M | $203.7M | $131.3M | $30.3M | $66.1M | $52.5M | $24.8M | $12.9M | $8.1M | $3.7M |
| Current Liabilities | $70.7M | $47.9M | $26.6M | $33.3M | $13.6M | $10.7M | $10.2M | $6.7M | $3.9M | $6.9M | $2.5M | $2.0M | $27.3M |
| Total Debt | - | $20.6M | $20.2M | $4.6M | $0 | - | $7.7M | $10.0M | $10.0M | - | - | - | - |
| Shareholders' Equity | $722.2M | $671.6M | $442.0M | $395.1M | $187.7M | $120.0M | $15.8M | $51.3M | $38.5M | -$61.9M | -$45.3M | $6.0M | -$23.9M |